Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remicade in insulin resistant obesity
NCT00636142Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Sep 2005
- Primary completion
- Jun 2007
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in insulin resistance (IR) and metabolic syndrome comparing Infliximab with Placebo (2 arms). Primary endpoint: Change in fasting insulin levels at 70 days. Started Sep 2005; status: completed.
02
Drugs
infliximab
03
Conditions
insulin resistance (IR)metabolic syndrome
Beyond the preview
Go deeper on NCT00636142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636142.